Business
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study initiation on track for mid-2026. Independent, blinded biomechanical gait analyses of the CONNECT SCI study designed to differentiate genuine neural recovery from compensatory movement remain ongoing, with results anticipated in 2Q 2026.Successfully listed on Nasdaq under the symbol 'NGEN' on Janu
About this update from Nervgen Pharma Corp.
[{"type":"image","alt":"NervGen Pharma Corp.","displaySize":"","headline":null,"caption":"NervGen Pharma Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/0d20e81fbabc5cf778f980fa5d3f3b22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i5INdPySLWrg54h80Wunyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOQ--/https://media.zenfs.com/en/globenewswire.com/0d20e81fbabc5cf778f980fa5d3f3b22","width":300,"height":92},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/i5INdPySLWrg54h80Wunyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOQ--/https://media.zenfs.com/en/globenewswire.com/0d20e81fbabc5cf778f980fa5d3f3b22","width":300,"height":92}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study initiation on track for mid-2026. ","length":235,"tagName":"p"}]},{"val":[{"type":"text","content":"Independent, blinded biomechanical gait analyses of the CONNECT SCI study designed to differentiate genuine neural recovery from compensatory movement remain ongoing, with results anticipated in 2Q 2026.","length":203,"tagName":"p"}]},{"val":[{"type":"text","content":"Successfully listed on Nasdaq under the symbol 'NGEN' on January 8, 2026, and voluntarily delisted from the TSX Venture Exchange.","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened leadership team with three senior appointments to support late-stage clinical development and Nasdaq listing. ","length":122,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":697,"olType":false},{"type":"text","content":"VANCOUVER, British Columbia, May 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported financial results for the first quarter ended March 31, 2026, and provided business updates.","length":424,"tagName":"p"},{"type":"text","content":""With the achievement of FDA alignment on the study parameters of RESTORE, our reg...